Efficacy was assessed by tumor growth, immune responses via flow cytometry, ELISA, ELISpot and cytotoxicity assays, safety via body/organ weight and serum markers.<h4>Results</h4>HER2 ECD mRNA-LNPs exhibited >80% encapsulation efficiency and narrow particle size distribution. This evidence concerns the gene ERBB2 and neoplasm.